Hepatobiliary Bowel Study
Hepatobiliary Bowel Study (HPB)
For information about the HPB Study, please contact Dr. Alice Wei at 416-340-3111 x2890.
|
|
|
- Home
- Staff
- GI Cancers
- Familial Gastrointestinal Cancer Registry
- About Us
- News and Events
- Diseases
- Frequently Asked Questions
- Kids' Korner
- Newsletter and Resources
- Physician Referrals
- Resources
- Glossary
- Professional Publications
- Professional Publications 2012
- Professional Publications 2011
- Professional Publications 2010
- Professional Publications 2009
- Professional Publications 2008
- Professional Publications 2007
- Professional Publications 2006
- Professional Publications 2005
- Professional Publications 2004
- Professional Publications 2003
- Professional Publications 2002
- Professional Publications 2001
- Professional Publications 2000
- Professional Publications Archives
- Professional Publications 2013
- Information Guides
- Web Links
- Behavior and Cognition in APC Study
- Diseases
- Ontario Pancreas Cancer Study (OPCS)
- Ontario Familial Colon Cancer Registry
- Soft Tissue Sarcoma Research Program
- Canadian Colorectal Cancer Consortium
- Familial Gastrointestinal Cancer Registry
- IBD
- What is Inflammatory Bowel Disease (IBD)?
- News and Events
- Current Research
- Crohn's and Colitis Canada IBD GEM Project
- Identification of Genes
- Hepatobiliary Bowel Study
- The ENABLE Study
- CAM Study
- The SAFE Study
- The IMPACT Study
- CD Study on subcutaneous medication
- Characterization of the Intestinal Microbiome
- Diet intervention as a prebiotic treatment for active ulcerative colitis
- Tissue (Biopsy) collections, Stool collections and Dietary Information
- Genetic Analysis of Infliximab-treated Inflammatory Bowel Disease Patients
- ICARUS-IBD
- Diverse Ancestry Study in IBD
- Clinical Trial for a dietary approach Crohn's Disease
- Clinical Trial for a oral medication in CD
- Mechanisms of Intestinal Inflammation Following Ileal Resection for Crohn's Disease
- Barriers and Facilitators to medication compliance in IBD patients
- Etrolizumab in UC: Etrolizumab/placebo for anti-TNF naive patients
- RHB-104 in CD
- Etrolizumab in CD
- Etrolizumab in UC: Etrolizumab/placebo for patients who are refractory/intolerant to TNF inhibitors
- APD334-003 (S1P1 receptor antagonist) in UC
- Humira (open label) and Methotrexate in UC
- Evolution of the Microbiome in a Pelvic Pouch Model: A Prospective Study to Understand Mechanisms of Ileal Inflammation
- The UC Relapse Study: Gene expression profiles and microbial predictors of relapse in Ulcerative Colitis
- IBD PACE Program
- FUNCTIon Trial
- Preconception and Pregnancy in IBD Program
- IBD Support Network
- Inflammatory Bowel Disease Group
- Medical Management for IBD Patients
- Orientation for new IBD patients visiting MSH
- IBD Well Sessions
- Medical Therapies and IBD
- Managing Stress in IBD
- Nutrition and IBD
- IBD Support Network
- Physician Education
- Newsletter and Resources
- Refer a Patient to a Gastroenterologist
- Surgical Q & A
- Surgical Programs
- Best Practice in General Surgery (BPIGS)
- Evidence Based Reviews in Surgery (EBRS)
- PICaSO
- Rachel M. Flood Education Program
- Events and News
- Ostomy Education Program
- Ostomy
- Living with an Ostomy
- Ostomy Care
- Caregivers Education
- IBD Patient Care Standards
- Nursing Care
- Patient Teaching
- Patient Engagement
- Ostomy Patient Teaching Guide
- 1. Appliance Change
- 2. The Stoma
- 3. Protection of Peristomal Skin and the Stoma
- 4. Resumption of Activities
- 5. Clothing
- 6. Personal Hygiene
- 7. Odour Control
- 8. Managing Flatus
- 9. Constipation
- 10. High Ileostomy Output
- 11. Food Blockage (Ileostomy)
- 12. Dehydration and Electrolyte Imbalance (Ileostomy)
- 13. Dietary Modifications
- 14. Medication Considerations
- 15. Travelling Tips
- 16.Sexuality/Intimacy
- 17. Resources and Supplies
- Pelvic Pouch - Patient Teaching Guide
- Care Plans
- Case Studies - Introduction
- Test Your Knowledge
- Ostomy Patient Care Standards
- Innovation in Ostomy Care Exhibit
- ZCC News
- Contact Us
- Partner with Us